NCT00234195

Wellbutrin XL, Major Depressive Disorder and Breast Cancer

A Pilot Study of the Efficacy and Tolerability of Bupropion Extended Release (Wellbutrin XL) for the Treatment of Major Depressive Disorder in Women With Breast Cancer

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 25 (planned)
• Sponsor: Thomas Jefferson University · Academic / Other
• Sex: Female
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

* To evaluate the efficacy of bupropion extended release (Wellbutrin XL™) in the treatment of Major Depressive Disorder in women with breast cancer. * To evaluate the tolerability of bupropion extended-release (Wellbutrin XL™) in these patients

Detailed description

This is research study for women diagnosed with breast cancer and major depression. Women with breast cancer who are depressed may report greater pain, poorer quality of life and worse overall functioning than those without depression. The study will determine whether or not bupropion extended release (Wellbutrin XLTM) is useful in lessening the symptoms of depression in women with breast cancer. One reason for conducting this research with bupropion extended release (Wellbutrin XLTM) instead of another antidepressant is because bupropion has a lower likelihood of causing the side effects of weight gain, sexual dysfunction, and fatigue, which may be important for women with breast cancer and may even have a beneficial effect on these symptoms. Bupropion extended release (Wellbutrin XL™)is approved by the United States Food and Drug Administration (FDA) for the treatment of major depression.

Conditions

• Breast Cancer
• Major Depressive Disorder

Interventions

Type	Name	Description
DRUG	bupropion extended release (Wellbutrin XL)

Timeline

• Start date: 2005-09-01
• Completion: 2007-01-01
• First posted: 2005-10-06
• Last updated: 2007-04-17

Locations

1 site across 1 country: United States